Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17035493 | 0.74 | ACHE (0.46) | ACHEMYCPDK2CD44CA1 | |
| SCHEMBL29967714 | 0.74 | CES2 (0.37) | PTGS2PTGS1CTSLCTSSCTSK | |
| SCHEMBL1868825 | 0.74 | CES2 (0.37) | PTGS2PTGS1CTSLCTSSCTSK | |
| SCHEMBL30213190 | 0.74 | HSD11B1 (0.42) | ACHEPTGS2 | |
| SCHEMBL1133195 | 0.73 | ACHE (0.56) | ACHEMYCPDK2CA1CA2 | |
| SCHEMBL5716618 | 0.72 | CTSL (0.44) | PTGS2PTGS1CTSLCTSSCTSK | |
| SCHEMBL1133108 | 0.72 | MAPK14 (0.47) | ACHEPTGS2 | |
| SCHEMBL17858130 | 0.72 | TRPA1 (0.42) | ACHEMYCPDK2CA1CA2 | |
| SCHEMBL4328219 | 0.72 | CTSL (0.46) | CTSLCTSSCTSK | |
| Water SCHEMBL5503134 | 0.72 | CES2 (0.36) | PTGS2PTGS1CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2287141-B1 | METHOD FOR PRODUCING UNSATURATED ORGANIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-8237002-B2 | Method for producing unsaturated organic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-07 | — | — | US | disclosed |
| US-20110046380-A1 | METHOD FOR PRODUCING UNSATURATED ORGANIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| EP-2287141-A1 | METHOD FOR PRODUCING UNSATURATED ORGANIC COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2011-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046380-A1 | METHOD FOR PRODUCING UNSATURATED ORGANIC COMPOUND | NIT2, NOS1, CHRM1 | ACHE 3440/4885PTGS2 352/4885PTGS1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.